Literature DB >> 20737577

A role for regulatory T cells in acceptance of ESC-derived tissues transplanted across an major histocompatibility complex barrier.

Kathy O Lui1, Ashleigh S Boyd, Stephen P Cobbold, Herman Waldmann, Paul J Fairchild.   

Abstract

We have previously reported that ESC-derived tissues are subject to some level of immune privilege, which might facilitate induction of immune tolerance. Herein, we further demonstrate that fully allogeneic ESC-derived tissues are accepted with a regimen of coreceptor blockade even in recipients known to be relatively resistant to such a tolerizing protocol. Moreover, ESC-derived tissues could be spontaneously accepted across a class I major histocompatibility complex disparity. We further show that CD4(+)FoxP3(+) regulatory T cells (Treg) appear to be essential for this natural "privileged" state as their ablation with an anti-CD25 mAb results in rejection of ESC-derived tissue. This same treatment exposes activation of macrophages and effector CD8(+) T cells, suggesting that these cells are subject to regulatory T cell control. Thus, spontaneous acceptance of ESC-derived tissues mimics the acquired immune privilege induced by coreceptor blockade and is determined by Treg-mediated suppression.

Entities:  

Mesh:

Year:  2010        PMID: 20737577     DOI: 10.1002/stem.506

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  15 in total

Review 1.  The challenge of immunogenicity in the quest for induced pluripotency.

Authors:  Paul J Fairchild
Journal:  Nat Rev Immunol       Date:  2010-12       Impact factor: 53.106

Review 2.  Potential barriers to therapeutics utilizing pluripotent cell derivatives: intrinsic immunogenicity of in vitro maintained and matured populations.

Authors:  Chad Tang; Micha Drukker
Journal:  Semin Immunopathol       Date:  2011-04-11       Impact factor: 9.623

3.  Bioengineering heart muscle: a paradigm for regenerative medicine.

Authors:  Gordana Vunjak-Novakovic; Kathy O Lui; Nina Tandon; Kenneth R Chien
Journal:  Annu Rev Biomed Eng       Date:  2011-08-15       Impact factor: 9.590

4.  Engraftment of embryonic stem cells and differentiated progeny by host conditioning with total lymphoid irradiation and regulatory T cells.

Authors:  Yuqiong Pan; Dennis B Leveson-Gower; Patricia E de Almeida; Antonio Pierini; Jeanette Baker; Mareike Florek; Hidekazu Nishikii; Byung-Su Kim; Rong Ke; Joseph C Wu; Robert S Negrin
Journal:  Cell Rep       Date:  2015-03-24       Impact factor: 9.423

Review 5.  Immunogenicity of pluripotent stem cells and their derivatives.

Authors:  Patricia E de Almeida; Julia D Ransohoff; Abu Nahid; Joseph C Wu
Journal:  Circ Res       Date:  2013-02-01       Impact factor: 17.367

Review 6.  Immunogenicity of in vitro maintained and matured populations: potential barriers to engraftment of human pluripotent stem cell derivatives.

Authors:  Chad Tang; Irving L Weissman; Micha Drukker
Journal:  Methods Mol Biol       Date:  2013

Review 7.  Effects of histocompatibility and host immune responses on the tumorigenicity of pluripotent stem cells.

Authors:  Ralf Dressel
Journal:  Semin Immunopathol       Date:  2011-04-04       Impact factor: 9.623

8.  Promoting long-term survival of insulin-producing cell grafts that differentiate from adipose tissue-derived stem cells to cure type 1 diabetes.

Authors:  Shuzi Zhang; Hehua Dai; Ni Wan; Yolonda Moore; Zhenhua Dai
Journal:  PLoS One       Date:  2011-12-28       Impact factor: 3.240

9.  F4/80+ Host Macrophages Are a Barrier to Murine Embryonic Stem Cell-Derived Hematopoietic Progenitor Engraftment In Vivo.

Authors:  Heather L Thompson; Nico van Rooijen; Bryce T McLelland; Jennifer O Manilay
Journal:  J Immunol Res       Date:  2016-10-30       Impact factor: 4.818

Review 10.  Immunogenicity and tumorigenicity of pluripotent stem cells and their derivatives: genetic and epigenetic perspectives.

Authors:  Yuan Tan; Sarah Ooi; Lisheng Wang
Journal:  Curr Stem Cell Res Ther       Date:  2014-01       Impact factor: 3.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.